Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

A Third-Generation Lentivirus Vector with a Conditional Packaging System

A New-Generation Stable Inducible Packaging Cell Line for Lentiviral Vectors.

A Self-Deletion Lentiviral Vector to Reduce the Risk of Replication-Competent Virus Formation

A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors

Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathway

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

A Single-Ltr HIV-1 Vector Optimized for Functional Genomics Applications

Transactivator and Structurally Optimized Inducible Lentiviral Vectors.

[High-titer preparation of HIV-1-based defective lentivector and it mediated efficient gene transfer]

Lentiviral Delivery of Proteins for Genome Engineering

Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors

Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences

Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization

Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector

Continuous high-titer HIV-1 vector production

Re-Designed Recombinant Hepatitis B Virus Vectors Enable Efficient Delivery of Versatile Cargo Genes to Hepatocytes with Improved Safety.

Improved Biosafety of a Lentiviral Vector by Reducing Cellular Gene Activation

Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice

Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vector.